AC Immune (NASDAQ:ACIU) Earns Sell (D-) Rating from Weiss Ratings

AC Immune (NASDAQ:ACIU)‘s stock had its “sell (d-)” rating reissued by research analysts at Weiss Ratings in a note issued to investors on Friday,Weiss Ratings reports.

Several other analysts have also weighed in on ACIU. BTIG Research reissued a “buy” rating and issued a $8.00 target price on shares of AC Immune in a report on Monday, September 8th. Zacks Research raised AC Immune from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 9th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

AC Immune Price Performance

Shares of ACIU stock opened at $3.25 on Friday. The business’s fifty day moving average price is $2.66 and its 200 day moving average price is $2.16. AC Immune has a 1-year low of $1.43 and a 1-year high of $3.99. The firm has a market capitalization of $326.33 million, a PE ratio of -5.60 and a beta of 1.56.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.05). AC Immune had a negative return on equity of 49.35% and a negative net margin of 174.94%.The business had revenue of $1.65 million for the quarter, compared to analyst estimates of $1.98 million. Equities research analysts expect that AC Immune will post -0.62 earnings per share for the current fiscal year.

Institutional Trading of AC Immune

A number of large investors have recently made changes to their positions in the stock. Sei Investments Co. acquired a new stake in shares of AC Immune during the second quarter valued at $51,000. Banque Cantonale Vaudoise acquired a new stake in shares of AC Immune during the first quarter valued at $50,000. Acadian Asset Management LLC boosted its stake in shares of AC Immune by 87.1% during the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock valued at $679,000 after acquiring an additional 172,796 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of AC Immune during the third quarter valued at $549,000. Finally, BVF Inc. IL boosted its stake in shares of AC Immune by 1.5% during the first quarter. BVF Inc. IL now owns 19,822,436 shares of the company’s stock valued at $37,068,000 after acquiring an additional 300,000 shares during the last quarter. Institutional investors and hedge funds own 51.36% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.